Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Official Title

An Open-Label, Multicentre, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients With Relapsed or Refractory Multiple Myeloma


This is a phase I, multicentre, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

Trial Description

Primary Outcome:

  • Incidence and Severity of Adverse Events (AEs)
Secondary Outcome:
  • Cmax
  • Objective Response Rate (ORR)
  • Duration of Response
  • Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)
  • Minimum observed serum concentration (Cmin)
  • Area Under the Concentration-Time Curve
  • Clearance (CL)
  • Volume of Distribution at Steady State (Vdss)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society